Despite high demand for an option like Journavx, doctors fear the drug’s price could be a hangup for insurers and limit ...

Vertex Pharmaceuticals Inc. is known worldwide for its cystic fibrosis medicines. The Boston drugmaker has won ... not a pill. Building up to a ‘blockbuster’ Myles Minter, a biotech analyst ...

Detailed price information for Vertex Inc Cl A (VERX-Q) from The Globe and Mail including charting and trades.

HAPPY BIRTHDAY — to David Edelman, Ropes & Gray’s Abby Cable; former Gov. Charlie Baker senior adviser and the NCAA’s Tim ...

More than 60 WBUR listeners and readers shared their stories — and photos — with us to collectively commemorate, rage and ...

Boston’s biggest lease deals in 2024 were all renewals, per Cushman & Wakefield’s research, mostly to keep the same space or add more: Vertex ... work for culture-building and mentorship.

ZUG, Switzerland and BOSTON, Jan. 13, 2025 (GLOBE NEWSWIRE ... Ph.D., Chairman and Chief Executive Officer of CRISPR Therapeutics. “Building on the success of CASGEVY’s launch, we continue ...

Today, she serves as senior director of employee relations at Vertex Pharmaceuticals ... gift for BC’s humanities building that bears their name, supporting his lifelong interest in the liberal arts.

That’s the opinion of top Vertex Pharmaceuticals executives and several market analysts about the Boston-based company’s painkiller Journavx, which the Food and Drug Administration approved on ...

The drug represents a new pathway to treating people with pain due to surgeries or traumatic injuries, avoiding the addictive risks of opioids.

The U.S. Food and Drug Administration said it approved Boston-based Vertex Pharmaceuticals' Journavx for short-term pain that often follows surgery or injuries. It’s the first new ...

It's the first new pharmaceutical approach to treating pain in over 20 years, designed to eliminate risks of addiction and ...